Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 10557 Views
-
Last post by NHE
-
- 0 Replies
- 1000 Views
-
Last post by NHE
-
- 0 Replies
- 1808 Views
-
Last post by frodo
-
- 0 Replies
- 1142 Views
-
Last post by frodo
-
- 0 Replies
- 1932 Views
-
Last post by NHE
-
- 0 Replies
- 1620 Views
-
Last post by frodo
-
- 0 Replies
- 1157 Views
-
Last post by NHE
-
- 1 Replies
- 1558 Views
-
Last post by frodo
-
- 0 Replies
- 2186 Views
-
Last post by NHE